November 26, 2024
SAN DIEGO — In patients with metabolic dysfunction–associated steatotic liver disease (MASLD), hypertension, and cirrhosis, certain antihypertensive medications may lead to increased risks for hepatocellular carcinoma […]
November 25, 2024
TOPLINE: Metabolic dysfunction–associated steatotic liver disease (MASLD), MASLD with increased alcohol intake (MetALD), and other combination etiologies of steatotic liver disease (SLD) are linked to a […]
November 25, 2024
SAN DIEGO — In patients with metabolic dysfunction–associated steatotic liver disease (MASLD), bariatric surgery appears to carry a lower risk for mortality after 5 years than […]
November 22, 2024
TOPLINE: Patients with stages I-III screen-detected colorectal cancer (CRC) have better disease-free survival rates than those with non-screen–detected CRC, an effect that was independent of patient, […]
November 22, 2024
SAN DIEGO — An artificial intelligence (AI)–driven algorithm may be able to accurately detect early-stage metabolic dysfunction–associated steatotic liver disease (MASLD) based on imaging findings and […]
November 22, 2024
TOPLINE: Exposure to antitumor necrosis factor (anti-TNF) therapy during the first 140 days of pregnancy is associated with a significant decrease in the risk of developing […]
November 21, 2024
SAN DEIGO — Semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, appears to safely and effectively treat metabolic dysfunction–associated steatohepatitis (MASH) among patients with moderate to […]
November 20, 2024
SAN DIEGO — Since the adoption of the most recent Model for End-Stage Liver Disease (MELD 3.0) scoring system by the federal Organ Procurement and Transplantation […]
November 20, 2024
TOPLINE: Adding Helicobacter pylori stool antigen (HPSA) testing to a fecal immunochemical test (FIT)–based colon cancer screening program did not reduce gastric cancer incidence or mortality […]